Company news
Crispr Therapeutics Ag (NASDAQ:CRSP) news
Crispr Therapeutics Ag news releases on 6ix. Latest, May 31, 2022: CRISPR Therapeutics to Host Innovation Day on June 21, 2022
Press releases — page 3
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
May 30, 2022
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
May 15, 2022
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
May 11, 2022
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 8, 2022
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
May 3, 2022
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting
March 7, 2022
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 14, 2022
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 8, 2022
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
February 1, 2022
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies
November 21, 2021
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
November 15, 2021
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 2, 2021
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies
October 11, 2021
CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
October 4, 2021
CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
September 30, 2021
CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
September 27, 2021
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 4, 2021
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
July 28, 2021
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
June 14, 2021
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
June 10, 2021
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
May 11, 2021
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
May 5, 2021
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
April 27, 2021
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
April 26, 2021
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
April 19, 2021
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
April 9, 2021
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 5, 2021
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
March 9, 2021
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
February 15, 2021
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
February 4, 2021
CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
January 31, 2021
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
December 13, 2020
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
December 4, 2020
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
November 15, 2020
CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
November 3, 2020
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
October 27, 2020
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
October 20, 2020
CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
October 6, 2020
CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
September 21, 2020
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
September 2, 2020
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
July 26, 2020
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
June 29, 2020
CRISPR Therapeutics Announces Proposed Offering of Common Shares
June 28, 2020
CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility
June 24, 2020
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
June 11, 2020
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
May 14, 2020
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
May 13, 2020
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
May 10, 2020
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
May 6, 2020